Regarding the patent lawsuit initiated by Illumina against MGI in Hong Kong, the specific impact has yet to be determined.

MGI believes that this patent litigation is an obvious attempt by Illumina to maintain a monopolistic market position and suppress the development of the industry. We intend to vigorously defend our intellectual property, and we have filed patent litigation against Illumina in U.S. District Court in California and Delaware.

MGI has an extensive patent portfolio in the field of gene sequencing, and its original intention has been to "provide the world with the right to another choice." MGI will continue to provide effective and affordable healthcare technologies and products for all.